IMARA

Imara, Inc. is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687, is a selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Brookline, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial

Imara Reports Second Quarter 2020 Financial Results and Business Highlights

Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease

Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease

BOSTON, Aug.  07, 2020  (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 14, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and other business updates.

Imara to Webcast Conference Call of Second Quarter 2020 Financial Results

BOSTON, July  30, 2020  (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, IMR-687, for the treatment of beta-thalassemia. The FDA previously granted Orphan Drug designation for IMR-687 for the treatment of patients with beta-thalassemia and Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of patients with sickle cell disease.

Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia

BOSTON, June  29, 2020  (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it was added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens on July 1, as part of the 2020 Russell U.S. Indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value indexes.

Imara Added to Membership of U.S. Small-Cap Russell 2000® Index

Bio-Rad Laboratories

Forma Therapeutics Holdings

Keros Therapeutics

Vaxcyte

Avidity Biosciences

Repare Therapeutics

SPDR S&P Biotech ETF

Zentalis Pharmaceuticals

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Biotech IPOs are booming -- but it's not all about Covid-19

Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia

Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders

BOSTON, Mass., June  24, 2020  (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia. The FDA previously granted Orphan Drug Designation for IMR-687 for the treatment of patients with sickle cell disease.

Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia

Imara Inc. IMRA, +12.66% announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment.

Imara reports promising data from mid-stage trial for sickle cell treatment

Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks of monotherapy

Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress

News for IMARA Stock (IMRA)